Author:
Chun Hoon Jai,Park Seun Ja,Lim Yun Jeong,Song Si Young
Publisher
Springer Nature Singapore
Reference28 articles.
1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 5 July 2021.
2. NCCN. Antiemesis (Version1.2021); 2021. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 5 July 2021.
3. Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M, et al. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Support Care Cancer. 2016;24(4):1563–9.
4. Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6(10):765–72.
5. Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer. 2011;19(Suppl 1):S43–7.